Esperion Therapeutics ESPR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $156.16M+36.2% | $167.85M+16.0% | $92.45M-36.1% | $86.06M-54.5% | $114.63M-49.4% | ||
| $499.27M+72.4% | $448.21M+70.5% | $388.16M+67.8% | $337.01M+63.5% | $289.62M+55.3% | ||
| $104.21M+4.9% | $105.12M+11.3% | $108.54M+35.5% | $114.47M+35.5% | $99.32M+35.9% | ||
| $459.46M+44.1% | $462.57M+36.9% | $360.46M+17.2% | $342.6M-0.7% | $318.78M-12.8% | ||
| $311K+36.4% | $338K+33.1% | $175K-37.7% | $201K-34.5% | $228K-14.9% | ||
| $56K0.0% | $56K0.0% | $56K0.0% | $56K0.0% | $56K0.0% | ||
| $462.53M+42.7% | $465.89M+35.5% | $364.02M+15.9% | $347.09M-1.5% | $324.03M-13.1% | ||
| $68.41M-5.0% | $65.07M+26.0% | $77.51M+122% | $74.7M+56.7% | $71.99M+153% | ||
| $43.53M+858% | $34.48M+305% | $30.68M+103% | $22.31M+7.9% | $4.54M-84.5% | ||
| $300.36M+10.8% | $300.81M+22.2% | $359.03M+116% | $298.8M+70.4% | $270.97M+64.7% | ||
| $152.67M— | $152.22M— | $151.65M— | —— | —— | ||
| $770.46M+2.7% | $767.85M+4.8% | $815.38M+19.2% | $780.59M+12.1% | $750.24M+12.4% | ||
| 480M0.0% | 480M0.0% | 480M0.0% | 480M0.0% | 480M0.0% | ||
| -$1.65B-0.5% | -$1.62B-1.4% | -$1.69B-6.7% | -$1.65B-6.7% | -$1.64B-10.3% | ||
| -$307.93M+27.8% | -$301.97M+22.3% | -$451.36M-21.9% | -$433.51M-25.9% | -$426.21M-44.8% | ||
| $462.53M+42.7% | $465.89M+35.5% | $364.02M+15.9% | $347.09M-1.5% | $324.03M-13.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Esperion Therapeutics's total assets?
- Esperion Therapeutics (ESPR) holds $462.5M in total assets, up 42.7% year over year.
- How much debt does Esperion Therapeutics have?
- Esperion Therapeutics carries $155.2M in total debt against -$307.9M of shareholders' equity, a debt-to-equity ratio of 0.75.
- How much cash does Esperion Therapeutics have?
- Esperion Therapeutics holds $156.2M in cash and equivalents.
- Can Esperion Therapeutics cover its short-term obligations?
- Its current ratio is 1.53 — current assets exceed current liabilities.
- Where does Esperion Therapeutics's balance sheet data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
